Cadherin-23(CDH23) is correlated with diffuse large B-cell lymphoma (DLBCL) tumor formation, according to a study published in Aging.
To conduct this study, researchers used the Gene Expression Profiling Interactive Analysis (GEPIA) and the Gene Expression Omnibus (GEO) databases to assess the CDH23 expression level in DLBCL with the prognostic value was analyzed via GEPIA. Correlated genes, target kinase, target miRNA, target transcription factor and biological functions were discerned using the LinkedOmics and GeneMANIA databases.
According to the results, the expression of CDH23 was reduced by DNA methylation significantly in DLBCL tissue. Reduction of CDH23 represented poor outcome of DLBCL patients. Functional enrichment analysis showed that CDH23 mainly enriched in cancer cell growth, cell metastasis, cell adhesion, cell cycle, drug catabolic process, leukocyte mediated immunity and DNA repair by some cancer related kinases, miRNAs and transcription factors.
“These results indicated that methylated reduction of CDH23 represented poor outcome of DLBCL,” the authors wrote. “CDH23 is associated with essential biological functions and key molecules in DLBCL. CDH23 may play crucial roles in DLBCL tumorigenesis.Our results lay a foundation for further investigation of the role of CDH23 in DLBCL tumorigenesis.”